Product image of Mowel (Mycophenolate Mofetil) supplied by GNH India

Mowel

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mowel (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mowel, is an antimetabolite immunosuppressant presented as an oral tablet formulation for oral administration. It is used to prevent acute and chronic organ transplant rejection and to treat lupus nephritis, helping to control immune‑mediated damage in adult patients.

GNH India supplies Mowel as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, pharmacies and clinical procurement teams across global markets while adhering to stringent quality and regulatory standards through continuous monitoring.

Manufacturer / TM Owner

Tecnimede - Sociedade Técnico-Medicinal, Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mowel (mycophenolate mofetil) acts on the immune system to inhibit lymphocyte proliferation, making it valuable in transplant and autoimmune disease management.
  • Organ transplant rejection: prevents acute and chronic rejection after kidney, heart, liver or lung transplantation.
  • Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus.
  • Maintenance therapy post‑transplant: supports long‑term graft survival as part of combination immunosuppressive regimens.

How It Works

  • Mycophenolate mofetil is a pro‑drug that is converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). By blocking IMPDH, the synthesis of guanine nucleotides is reduced, limiting DNA replication in activated T and B lymphocytes. Consequently, the drug diminishes the immune response that leads to graft rejection or autoimmune kidney damage.

Side Effects

Mycophenolate mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Headache

Serious or Rare Side Effects

  • Bone marrow suppression (leukopenia, anemia, thrombocytopenia)
  • Hepatotoxicity (elevated liver enzymes, hepatitis)
  • Progressive multifocal leukoencephalopathy (PML)

Precautions & Warnings

When prescribing Mowel, clinicians should observe several safety precautions to minimize risk.

  • Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia.
  • Monitor liver function: assess hepatic enzymes periodically for signs of hepatotoxicity.
  • Avoid use in pregnancy: the drug is contraindicated (Category X) due to teratogenic risk.
  • Use effective contraception: both male and female patients must employ reliable birth control during treatment and for several weeks after discontinuation.
  • Adjust dose in renal impairment: reduce dosage in patients with reduced creatinine clearance as advised by the prescriber.
  • Store below 25°C: keep in the original packaging, protect from moisture and heat.

Avoid Interactions

Mycophenolate mofetil interacts with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Live vaccines: may cause severe infection; avoid concurrent administration.
  • Antacids containing aluminum or magnesium: reduce mycophenolate absorption; separate dosing by at least 2 hours.
  • Azathioprine: additive bone‑marrow suppression; avoid combined use.
  • Ribavirin: increased risk of hematologic toxicity; avoid co‑administration.
  • Cyclosporine or tacrolimus: may raise mycophenolate levels, requiring dose adjustment.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: monitor renal function and potassium levels.
  • NSAIDs: may worsen renal impairment; assess kidney function regularly.

Frequently Asked Questions

Mowel contains mycophenolate mofetil, an immunosuppressive agent that is prescribed to prevent acute and chronic rejection after organ transplantation and to treat lupus nephritis, a kidney manifestation of systemic lupus erythematosus.

Mycophenolate mofetil is converted in the body to mycophenolic acid, which selectively blocks the enzyme inosine monophosphate dehydrogenase. This inhibition reduces guanine nucleotide production, limiting DNA synthesis in activated T and B lymphocytes and thereby suppressing the immune response.

The appropriate dose of Mowel is individualized by the prescribing clinician based on the patient’s indication, body weight, renal function, and concomitant therapies. Dosage adjustments are made according to therapeutic response and laboratory monitoring, not by a fixed schedule.

Mowel is classified as Pregnancy Category X because it has demonstrated teratogenic and embryotoxic effects. It is contraindicated in pregnant women, and women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, so use is generally avoided.

To order Mowel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine, mycophenolate mofetil offers a different mechanism by targeting nucleotide synthesis rather than calcium signaling. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing individual drug toxicity.

Mowel should be stored below 25 °C in its original container, protected from moisture and direct heat. Keep the package tightly closed, avoid exposure to humidity, and keep out of reach of children. No special refrigeration is required for this oral formulation.

Mowel is taken orally, usually as a tablet, with or without food as directed by the prescriber. The dose is divided throughout the day according to the treatment plan, and patients should follow the exact schedule provided to maintain consistent blood levels.

Serious risks include bone‑marrow suppression leading to leukopenia or anemia, hepatotoxicity, and rare opportunistic infections such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for blood count changes, liver enzyme elevations, and signs of infection.

Mowel is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate mofetil, and patients with severe uncontrolled infections. Caution is also advised for those with significant renal impairment, as dose adjustment may be required.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT